<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02433288</url>
  </required_header>
  <id_info>
    <org_study_id>D3560C00088</org_study_id>
    <nct_id>NCT02433288</nct_id>
  </id_info>
  <brief_title>Rosuvastatin Adherence App Study in China</brief_title>
  <acronym>eHELP China</acronym>
  <official_title>A Randomized, Two-arm, Open, 24-week Study to Evaluate the Effect of a Smart Phone-based Patient Support Tool on Duration of Treatment in Patients Prescribed Rosuvastatin in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, two-arm, open label, Phase IV clinical trial to evaluate if the
      provision of a smart phone-based patient support tool prolongs the patient's rosuvastatin
      treatment duration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomised, two-arm, open, Phase IV clinical trial to evaluate if the provision of
      a smart phone-based patient support tool prolongs the patient's rosuvastatin treatment
      duration.

      Patients diagnosed with dyslipidemia or hyperlipidemia at high risk and are treated with
      rosuvastatin will be offered participation in the study. Patients who accept and sign the
      Informed Consent will be randomised into one of two study groups:

        -  Active group: In this group, patients will have access to the smart phone-based patient
           support tool. The smart phone application used on the patients' smart phones will
           contain both the patient support tool and the questions for the clinical evaluation in
           the form of the Rosuvastatin Adherence questionnaire (RAQ), Beliefs about Medicine
           Questionnaire - General (BMQ-G), and a Lifestyle questionnaire (LSQ) on disease
           understanding, lifestyle and treatment awareness. Patients in the Active group will also
           receive feedback on their daily rosuvastatin treatment as entered in the patient support
           tool.

        -  Control group: In this group the patients will have no additional support beyond the
           commonly practiced patient information, i.e. the patients will have no access to the
           smart phone-based patient support tool. However, a smart phone application will be used
           to prompt patients with the questions for the clinical evaluation (RAQ, BMQ-G and LSQ).

      In this study, no rosuvastatin will be dispensed to the study participants i.e. patients will
      purchase their rosuvastatin prescription themselves as in normal practice. All assessments in
      this study (including blood sampling for the lipid profile) will not be used for guiding the
      treatment of patients in the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 20, 2015</start_date>
  <completion_date type="Actual">October 28, 2016</completion_date>
  <primary_completion_date type="Actual">October 28, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of Treatment</measure>
    <time_frame>limited to 169 days</time_frame>
    <description>The time from randomization to last patient reported visit (prior to the end-of-study visit) to a doctor to get a prescription for rosuvastatin plus the number of days of medicine provided in that last prescription.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Fully Adherent Patients</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>The number of patients who answered 'Yes' to Q4 of Rosuvastatin Adherence Questionnaire (RAQ) at all time points divided by the total number of randomized patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Adherence</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>The number of reported rosuvastatin tablets taken divided by the total number of days in the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Low-Density Lipoprotein-Cholesterol (LDL-C) From Baseline</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Low-Density Lipoprotein-Cholesterol (LDL-C) change from baseline at the Week 24 assessment for subjects who completed 24 weeks of treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">885</enrollment>
  <condition>Dyslipidemia</condition>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Active app</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The smart phone application used on the patients' smart phones will contain both the patient support tool and the questions for the clinical evaluation in the form of the Rosuvastatin Adherence questionnaire (RAQ), Beliefs about Medicine Questionnaire - General (BMQ-G), (Horne, 1999) and a Lifestyle questionnaire (LSQ) on disease understanding, lifestyle and treatment awareness. Patients in the Active group will also receive feedback on their daily rosuvastatin treatment as entered in the patient support tool.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control app</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>a smart phone application will be used to prompt patients with the questions for the clinical evaluation (RAQ, BMQ-G and LSQ).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Smart phone based patient support tool</intervention_name>
    <description>The smart phone application used on the patients' smart phones will contain both the patient support tool and the questions for the clinical evaluation in the form of the Rosuvastatin Adherence questionnaire (RAQ), Beliefs about Medicine Questionnaire - General (BMQ-G), (Horne, 1999) and a Lifestyle questionnaire (LSQ) on disease understanding, lifestyle and treatment awareness. Patients in the Active group will also receive feedback on their daily rosuvastatin treatment as entered in the patient support tool.</description>
    <arm_group_label>Active app</arm_group_label>
    <other_name>Active</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control application: only for data collection</intervention_name>
    <description>the patients will have no access to the smart phone-based patient support tool. However, a smart phone application will be used to prompt patients with the questions for the clinical evaluation (RAQ, BMQ-G and LSQ).</description>
    <arm_group_label>Control app</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent prior to any study specific procedures

          -  Female or male aged 18-80 years, diagnosed with dyslipidemia or hyperlipidemia at high
             risk and prescribed rosuvastatin

        Dyslipidemia or hyperlipidemia defined as:

        LDL-C≥2.6 mmol/L and TG&lt;4.52mmol/L

        High risk complies with any of the following:

          -  Documented cardiovascular disease (CVD) by invasive or non-invasive testing (such as
             coronary angiography, nuclear imaging, stress echocardiography, carotid plaque on
             ultrasound), previous myocardial infarction (MI), acute coronary syndrome (ACS),
             coronary revascularization [percutaneous coronary intervention (PCI), coronary artery
             bypass graft (CABG)] and other arterial revascularization procedures, ischaemic stroke
             and peripheral arterial disease (PAD).

          -  Patients with type 2 diabetes, patients with type 1 diabetes with target organ damage
             (such as microalbuminuria).

          -  Patients with moderate to severe chronic kidney disease [(CKD), glomerular filtration
             rate (GFR) &lt; 60 mL/min/1.73 m2].

               -  Patients must have a smart phone that is compatible with the patient support tool
                  and clinical evaluation questionnaire at their disposal and are comfortable with
                  using of interactive smart phone applications. The required specification for the
                  phone will be determined after completed testing.

               -  Ability to read, understand and write Chinese.

               -  Statin-naïve or with no statin use during the last 4 weeks prior to enrolment
                  except in the event of patients may receive at most 7 doses of statins during
                  current hospitalization before enrollment.

        Exclusion Criteria:

          -  Involvement in the planning and/or conduct of the study (applies to both AstraZeneca
             staff and/or staff at the study site)

          -  Previous enrolment or randomisation in the present study

          -  Participation in another clinical study with an investigational product or device
             during the last 30 days excluding prospective/retrospective register based studies
             that do not require any extra visits in addition to ordinary health care. Patients who
             withdraw from this study for any reason cannot re-enter the study.

          -  Patients in whom rosuvastatin is contraindicated i.e.

               -  patients with hypersensitivity to rosuvastatin or any of the excipients.

               -  patients with active liver disease including unexplained, persistent elevations
                  of serum transaminases and have serum transaminase elevation exceeding 3 x the
                  upper limit of normal (ULN).

               -  patients with severe renal impairment (creatinine clearance &lt;30 ml/min).

               -  patients with myopathy.

               -  patients receiving concomitant cyclosporin.

               -  females during pregnancy and lactation and women of childbearing potential who
                  are not using appropriate contraceptive measures.

          -  Significant medical or psychological condition that, in the opinion of the
             Investigator, would compromise the patient's safety or successful participation in the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan C Carlsson</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>100045</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>100049</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>100700</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>101199</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changsha</city>
        <zip>410005</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chengdu</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chongqing</city>
        <zip>400013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hang Zhou</city>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huzhou</city>
        <zip>313003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanchang</city>
        <zip>330009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shandong</city>
        <zip>262700</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200072</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200240</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>201199</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tianjin</city>
        <zip>300142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tianjin</city>
        <zip>300192</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tianjin</city>
        <zip>300211</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Waifang</city>
        <zip>261500</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wenzhou</city>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wuhan</city>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999 Dec;47(6):555-67.</citation>
    <PMID>10661603</PMID>
  </reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>April 29, 2015</study_first_submitted>
  <study_first_submitted_qc>April 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2015</study_first_posted>
  <results_first_submitted>September 28, 2017</results_first_submitted>
  <results_first_submitted_qc>August 31, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 31, 2019</results_first_posted>
  <last_update_submitted>August 31, 2018</last_update_submitted>
  <last_update_submitted_qc>August 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>smart phone-based</keyword>
  <keyword>rosuvastatin</keyword>
  <keyword>duration of treatment</keyword>
  <keyword>Treatment adherence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>885 patients signed Inform Consent and were randomized in the study, 443 subjects in the active group and 442 subjects in the control group. 320 (72.2%) and 316 (71.5%) patients, respectively, completed the study. The overall completion rate was 71.9%. 31 patients (12 and 19 respectively) was not successful in receiving the relevant application.</recruitment_details>
      <pre_assignment_details>A total of 885 patients were randomized (1:1) to two groups: an active group which received the smart phone-based patient support tool and a control application used for data collection only.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Active Group</title>
          <description>receive the smart phone-based patient support tool</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>provided only the control application and not the smart phone-based patient support tool</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="443"/>
                <participants group_id="P2" count="442"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="320"/>
                <participants group_id="P2" count="316"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="123"/>
                <participants group_id="P2" count="126"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Severe non-compliance to protocol</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Eligibility criteria not fullfilled</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
                <participants group_id="P2" count="99"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline characteristics were summarized based on the FAS, which comprised all randomized patients who received the study application successfully.</population>
      <group_list>
        <group group_id="B1">
          <title>Active Group</title>
          <description>receive the smart phone-based patient support tool</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>provided only the control application and not the smart phone-based patient support tool</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="431"/>
            <count group_id="B2" value="423"/>
            <count group_id="B3" value="854"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.7" spread="9.80"/>
                    <measurement group_id="B2" value="54.5" spread="9.51"/>
                    <measurement group_id="B3" value="54.6" spread="9.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="154"/>
                    <measurement group_id="B3" value="315"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="270"/>
                    <measurement group_id="B2" value="269"/>
                    <measurement group_id="B3" value="539"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="431"/>
                    <measurement group_id="B2" value="423"/>
                    <measurement group_id="B3" value="854"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="431"/>
                    <measurement group_id="B2" value="423"/>
                    <measurement group_id="B3" value="854"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Duration of Treatment</title>
        <description>The time from randomization to last patient reported visit (prior to the end-of-study visit) to a doctor to get a prescription for rosuvastatin plus the number of days of medicine provided in that last prescription.</description>
        <time_frame>limited to 169 days</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Active Group</title>
            <description>receive the smart phone-based patient support tool</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>provided only the control application and not the smart phone-based patient support tool</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Treatment</title>
          <description>The time from randomization to last patient reported visit (prior to the end-of-study visit) to a doctor to get a prescription for rosuvastatin plus the number of days of medicine provided in that last prescription.</description>
          <population>FAS</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="431"/>
                <count group_id="O2" value="423"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156.7" spread="2.24"/>
                    <measurement group_id="O2" value="146.0" spread="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0019</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Fully Adherent Patients</title>
        <description>The number of patients who answered 'Yes' to Q4 of Rosuvastatin Adherence Questionnaire (RAQ) at all time points divided by the total number of randomized patients.</description>
        <time_frame>Up to 24 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Active Group</title>
            <description>receive the smart phone-based patient support tool</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>provided only the control application and not the smart phone-based patient support tool</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Fully Adherent Patients</title>
          <description>The number of patients who answered 'Yes' to Q4 of Rosuvastatin Adherence Questionnaire (RAQ) at all time points divided by the total number of randomized patients.</description>
          <population>FAS</population>
          <units>% of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="431"/>
                <count group_id="O2" value="423"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                    <measurement group_id="O2" value="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0017</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Adherence</title>
        <description>The number of reported rosuvastatin tablets taken divided by the total number of days in the study.</description>
        <time_frame>Up to 24 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Active Group</title>
            <description>receive the smart phone-based patient support tool</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>provided only the control application and not the smart phone-based patient support tool</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Adherence</title>
          <description>The number of reported rosuvastatin tablets taken divided by the total number of days in the study.</description>
          <population>FAS</population>
          <units>% adherence</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.95" spread="32.916"/>
                    <measurement group_id="O2" value="58.19" spread="36.257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-20.24</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.39</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.91</ci_lower_limit>
            <ci_upper_limit>-13.57</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Reported Treatment Adherence</title>
        <description>The number of reported rosuvastatin tablets taken divided by the total number of days reported during the treatment. This is eliminated any missing data from the calculation.</description>
        <time_frame>Up to 24 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Active Group</title>
            <description>receive the smart phone-based patient support tool</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>provided only the control application and not the smart phone-based patient support tool</description>
          </group>
        </group_list>
        <measure>
          <title>Reported Treatment Adherence</title>
          <description>The number of reported rosuvastatin tablets taken divided by the total number of days reported during the treatment. This is eliminated any missing data from the calculation.</description>
          <population>FAS</population>
          <units>% adherence</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.63" spread="18.347"/>
                    <measurement group_id="O2" value="96.01" spread="14.316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3939</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.38</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.60</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.56</ci_lower_limit>
            <ci_upper_limit>1.80</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Low-Density Lipoprotein-Cholesterol (LDL-C) From Baseline</title>
        <description>Low-Density Lipoprotein-Cholesterol (LDL-C) change from baseline at the Week 24 assessment for subjects who completed 24 weeks of treatment</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Active Group</title>
            <description>receive the smart phone-based patient support tool</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>provided only the control application and not the smart phone-based patient support tool</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Low-Density Lipoprotein-Cholesterol (LDL-C) From Baseline</title>
          <description>Low-Density Lipoprotein-Cholesterol (LDL-C) change from baseline at the Week 24 assessment for subjects who completed 24 weeks of treatment</description>
          <population>FAS</population>
          <units>% change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.09" spread="1.40"/>
                    <measurement group_id="O2" value="-21.72" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7514</p_value>
            <method>ANCOVA</method>
            <method_desc>linear model including terms for randomized group and baseline LDL-C</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.63</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.99</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.27</ci_lower_limit>
            <ci_upper_limit>4.53</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>177±7 days</time_frame>
      <desc>This was an evaluation of the smart phone-based patient support tool, and rosuvastatin was not considered an investigational product for this study. There was no requirement to report AEs as part of the study, except the ones meeting the SAE criteria.
Other [Not Including Serious] Adverse Events were not monitored/assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Active Group</title>
          <description>receive the smart phone-based patient support tool</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>provided only the control application and not the smart phone-based patient support tool</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Cardiac insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Cardiac neurosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Complete right bundle branch block</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Coronary atherosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Coronary atherosclerotic heart disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="431"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Coronary heart disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="431"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Dilated cardiomyopathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Persistent atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Unstable angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Ventricular premature beat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Macular edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Somatization disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Limb mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute renal insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Chronic glomerulonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Pulmonary infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Left carotid artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Right carotid artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The secondary endpoints Percentage of fully adherent patients and Treatment adherence may be impacted by the response frequency to the relevant questions. There is a tendency to a higher response frequency in the Control group in this study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Traxler, Barry M</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>+1 301 398 0657</phone>
      <email>barry.traxler@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

